Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Moodys
Teva
Medtronic
Accenture
Express Scripts
Citi
Farmers Insurance
Deloitte

Generated: December 10, 2018

DrugPatentWatch Database Preview

Vicuron Company Profile

« Back to Dashboard

Summary for Vicuron
International Patents:64
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Vicuron

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes 5,965,525 ➤ Sign Up Y Y ➤ Sign Up
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes 7,709,444 ➤ Sign Up Y ➤ Sign Up
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes 6,960,564 ➤ Sign Up Y ➤ Sign Up
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes 7,709,444 ➤ Sign Up Y ➤ Sign Up
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes 6,960,564 ➤ Sign Up Y ➤ Sign Up
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes 5,965,525 ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Vicuron

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 6,384,013 ➤ Sign Up
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 6,384,013 ➤ Sign Up
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 6,743,777 ➤ Sign Up
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 6,743,777 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Vicuron Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00334 Netherlands ➤ Sign Up PRODUCT NAME: ANIDULAFUNGIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639/01 Switzerland ➤ Sign Up PRODUCT NAME: ANIDULAFUNGIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58325 03.09.2009
C002/2008 Ireland ➤ Sign Up SPC002/2008: 20081105, EXPIRES: 20180317
0334 Netherlands ➤ Sign Up 300334, 20130318, EXPIRES: 20180317
C0009 France ➤ Sign Up PRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
C/GB08/016 United Kingdom ➤ Sign Up PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
UBS
Julphar
Mallinckrodt
Chinese Patent Office
Merck
Cipla
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.